

SPECIFICATIONS OF THE NATIONAL VOLUNTARY CONSENSUS STANDARDS FOR AMBULATORY CARE USING CLINICALLY ENRICHED ADMINISTRATIVE DATA

Measure ID	Description	IP Owner
ASTHMA AND RESPIRATORY ILLNESS		
EC-234-08 Asthma-Short-Acting Beta Agonist Inhaler for Rescue Therapy CSAC Decision*: Endorse	Percentage of patients with asthma who have a refill for a short acting beta agonist in the past 24 months	Active Health
EC-016-08 Use of Spirometry Testing in the Assessment and Diagnosis of COPD CSAC Decision*: Endorse	This measure assesses the percentage of members 40 years of age and older with a new diagnosis or newly active chronic obstructive pulmonary disease (COPD) who received appropriate spirometry testing to confirm the diagnosis	NCQA
EC-255-08 COPD with Exacerbations- Adding a Long-Acting Bronchodilator CSAC Decision*: Endorse	Percentage of patients 35 years and older with COPD exacerbations that are receiving a long acting bronchodilator	Active Health
EC- 227-08 High Risk for Pneumococcal Disease - Pneumococcal Vaccination CSAC Decision*: Endorse	Percentage of patients age 5-64 with a high risk condition or age 65 years and older who received the pneumococcal vaccine	Active Health
BONE AND JOINT CONDITIONS		
EC-089-08 New Rheumatoid Arthritis Baseline ESR or CRP within Three Months CSAC Decision*: Endorse	This measure identifies adult patients newly diagnosed with rheumatoid arthritis during the first 8 months of the measurement year who received erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) lab tests either 4 months (3 months + 1-month grace period) before or after the initial diagnosis	Resolution Health

*CSAC's decisions are forwarded to the NQF Board of Directors for Ratification.

Measure ID	Description	IP Owner
BONE AND JOINT CONDITIONS		
<p>EC-060-08</p> <p>Rheumatoid Arthritis Annual ESR or CRP</p> <p>CSAC Decision*:</p> <p>Endorse</p>	<p>This measure identifies adult patients with a history of rheumatoid arthritis who have received erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) lab tests during the measurement year</p>	<p>Resolution Health</p>
<p>EC-056-08</p> <p>Rheumatoid Arthritis New DMARD Baseline Serum Creatinine</p> <p>CSAC Decision*:</p> <p>Endorse</p>	<p>This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline serum creatinine testing within 90 days before to 14 days after the new start of methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, cyclosporine, or cyclophosphamide during the measurement year</p>	<p>Resolution Health</p>
<p>EC-057-08</p> <p>Rheumatoid Arthritis New DMARD Baseline Liver Function Test</p> <p>CSAC Decision*:</p> <p>Endorse</p>	<p>This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline liver function testing (AST or ALT) within 90 days before to 14 days after the new start of sulfasalazine, methotrexate, leflunomide, azathioprine, cyclosporine or cyclophosphamide during the measurement year</p>	<p>Resolution Health</p>
<p>EC-059-08</p> <p>Rheumatoid Arthritis New DMARD Baseline CBC</p> <p>CSAC Decision*:</p> <p>Endorse</p>	<p>This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline complete blood count (CBC) testing within 90 days before to 14 days after the new start of sulfasalazine, methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, oral gold, cyclosporine, or cyclophosphamide during the measurement year</p>	<p>Resolution Health</p>

*CSAC's decisions are forwarded to the NQF Board of Directors for Ratification.

Measure ID	Description	IP Owner
BONE AND JOINT CONDITIONS		
EC-049-08 Hydroxychloroquine Annual Eye Exam CSAC Decision*: Endorse	This measure identifies the percentage of patients with Rheumatoid Disease who received hydroxychloroquine during the measurement year and had a fundoscopic examination during the measurement year or in the year prior to the measurement year	Resolution Health
EC-079-08 Methotrexate: LFT within 12 Weeks CSAC Decision*: Endorse	This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a liver function test (LFT) in the 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim	Resolution Health
EC-080-08 Methotrexate: CBC within 12 Weeks CSAC Decision*: Endorse	This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a CBC test within 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim	Resolution Health
EC-081-08 Methotrexate: Creatinine within 12 Weeks CSAC Decision*: Endorse	This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a serum creatinine test in the 120 days (3 months + 1 month grace period) after the earliest observed methotrexate prescription claim	Resolution Health
EC-283-08 Osteoporosis-Use of Pharmacologic Treatment CSAC Decision*: Endorse	Percentage of patients who have osteoporosis and are on osteoporosis therapy	Active Health

*CSAC's decisions are forwarded to the NQF Board of Directors for Ratification.

Measure ID	Description	IP Owner
BONE AND JOINT CONDITIONS		
EC-213-08 Steroid Use -Osteoporosis Screening CSAC Decision*: Endorse	Percentage of patients age 18 and older who have been on chronic steroids for at least 180 days in the past 9 months that have had a bone density evaluation to check for osteoporosis	Active Health
EC-281-08 Osteopenia and Chronic Steroid Use – Treatment to prevent Osteoporosis CSAC Decision*: Endorse	Percentage of patients, who are female and 55 years and older or male and 50 years and older, who have a diagnosis of osteopenia and are on long-term steroids (> 6 months) and who are on osteoporosis therapy	Active Health
CANCER SCREENING AND SURVEILLANCE		
EC-028-08 Annual Cervical Cancer Screening for High Risk Patients CSAC Decision*: Endorse	This measure identifies women age 12 to 65 diagnosed with cervical dysplasia (CIN 2), cervical carcinoma-in-situ, or HIV/AIDS prior to the measurement year, and who still have a cervix, who had a cervical CA screen during the measurement year	Resolution health
EC-240-08 Breast Cancer-Cancer Surveillance CSAC Decision*: Endorse	Percentage of female patients with breast cancer who had breast cancer surveillance in the past 12 months	Active Health
EC-007-08 Follow-Up after Initial Diagnosis and Treatment of Colorectal Cancer: Colonoscopy CSAC Decision*: Endorse	To ensure that all eligible members who have been newly diagnosed and resected with colorectal cancer receive a follow-up colonoscopy within 15 months of resection	Health Benchmarks
EC-248-08 Prostate Cancer – Cancer Surveillance CSAC Decision*: Endorse	Percentage of males with prostate cancer that have had their PSA monitored in the past 12 months	Active Health

*CSAC’s decisions are forwarded to the NQF Board of Directors for Ratification.

Measure ID	Description	IP Owner
CARDIOVASCULAR DISEASE		
EC-071-08 Post MI: ACE Inhibitor or ARB Therapy CSAC Decision*: Endorse	This measure identifies patients with ST elevation MI (STEMI), or non-ST elevation MI (NSTEMI) plus a history of hypertension, heart failure and/or diabetes prior to the measurement year who are taking an ACEI or an ARB during the measurement year.	Resolution Health
EC-208-08 MI-Use of Beta Blocker Therapy CSAC Decision*: Endorse	Percentage of patients who had a myocardial infarction (MI) and are taking a beta blocker	Active Health
EC-054-08 Stent Drug-Eluting Clopidogrel CSAC Decision*: Endorse	This measure identifies patients undergoing percutaneous coronary intervention (PCI) with placement of a drug-eluting intracoronary stent during the first 9 months of the measurement year, who filled a prescription for clopidogrel in the 3 months following stent placement	Resolution Health
EC-272-08 Secondary Prevention of Cardiovascular Events- Use of Aspirin or anti-platelet therapy CSAC Decision*: Endorse	Percentage of patients with ischemic vascular disease (IVD) that are taking aspirin or an anti-platelet agent	Active Health
EC-202-08 Heart Failure - Use of ACE Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) Therapy CSAC Decision*: Endorse	Percentage of patients with CHF that are on an ACE-I or ARB	Active Health
EC-215-08 Congestive Heart Failure-Use of a Beta Blocker CSAC Decision*: Endorse	Percentage of adult patients with congestive heart failure (CHF) that are on a beta blocker	Active Health

*CSAC's decisions are forwarded to the NQF Board of Directors for Ratification.

Measure ID	Description	IP Owner
CARDIOVASCULAR DISEASE		
EC-083-08 New Atrial Fibrillation: Thyroid Function Test CSAC Decision*: Endorse	This measure identifies patients with new-onset atrial fibrillation during the measurement year who have had a thyroid function test 6 weeks before or after the diagnosis of atrial fibrillation	Resolution Health
EC-244-08 Atrial Fibrillation - Warfarin Therapy CSAC Decision*: Endorse	Percentage of adult patients with atrial fibrillation and major stroke risk factors on warfarin	Active Health
EC-256-08 Male Smokers or Family History of Abdominal Aortic Aneurysm (AAA) Screening for AAA CSAC Decision*: Endorse	Percentage of men age 65-75 years with history of tobacco use or men age 60 yrs and older with a family history of abdominal aortic aneurysm who were screened for AAA	Active Health
EC-099-08 [Hypertension] patients with a serum creatinine in the last 12 months CSAC Decision*: Endorse	This measure identifies patients with hypertension (HTN) that had a serum creatinine in last 12 reported months	Ingenix
EC-037-08 Deep Vein Thrombosis Anticoagulation >= 3 Months CSAC Decision*: Endorse	This measure identifies patients with deep vein thrombosis (DVT) on anticoagulation for at least 3 months after the diagnosis	Resolution Health
EC-061-08 Pulmonary Embolism Anticoagulation >= 3 Months CSAC Decision*: Endorse	This measure identifies patients with pulmonary embolism (PE) on anticoagulation for at least 3 months after the diagnosis	Resolution Health

*CSAC's decisions are forwarded to the NQF Board of Directors for Ratification.

Measure ID	Description	IP Owner
CARDIOVASCULAR DISEASE		
EC-053-08 Tympanostomy Tube Hearing Test CSAC Decision*: Endorse	This measure identifies the percentage of patients age 2 through 12 years with OME who received tympanostomy tube(s) insertion during the measurement year and had a hearing test performed within 6 months prior to the initial tube placement	Resolution Health
CHRONIC KIDNEY DISEASE		
EC-006-08 Chronic Kidney Disease: Monitoring Parathyroid Hormone CSAC Decision*: Endorse	To ensure that members with chronic kidney disease, who are not undergoing dialysis, are monitored for PTH levels at least once annually	Health Benchmarks
EC-012-08 Chronic Kidney Disease: Monitoring Calcium CSAC Decision*: Endorse	To ensure that members with chronic kidney disease, but who are not on dialysis, are monitored for blood calcium levels at least annually	Health Benchmarks
EC-005-08 Chronic Kidney Disease: Monitoring Phosphorous CSAC Decision*: Endorse	To ensure that members with chronic kidney disease but who are not on dialysis are monitored for blood phosphorous levels at least once annually	Health Benchmarks
EC-251-08 Chronic Kidney Disease – Lipid Profile Monitoring CSAC Decision*: Endorse	Percentage of patients with chronic kidney disease that have been screened for dyslipidemia with a lipid profile	Active Health

*CSAC's decisions are forwarded to the NQF Board of Directors for Ratification.

Measure ID	Description	IP Owner
CHRONIC KIDNEY DISEASE		
EC-252-08 Chronic Kidney Disease with LDL Greater than or equal to 130 – consider adding a lipid lowering agent CSAC Decision*: Endorse	Percentage of patients with chronic kidney disease and an LDL greater than or equal to 130mg/dl that have a current refill for a lipid lowering agent	Active Health
EC-238-08 Non-Diabetic Nephropathy – consider adding and ACEI or ARB CSAC Decision*: Endorse	Percentage of patients with proteinuria that have a current refill for an angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)	Active Health
DIABETES		
EC-096-08 Adult(s) with diabetes that had a serum creatinine in the last 12 reported months CSAC Decision*: Endorse	This measure identifies adults with diabetes mellitus that had a serum creatinine test in last 12 reported months	Ingenix
EC-095-08 Adults(s) taking insulin with evidence of self-monitoring blood glucose testing CSAC Decision*: Endorse	This measure identifies patients with diabetes mellitus taking insulin that had evidence of self-monitoring blood glucose testing in last 12 reported months	Ingenix
EC-274-08 Primary prevention of cardiovascular events in diabetics older than 40 years – Use of aspirin or antiplatelet therapy CSAC Decision*: Endorse	Percentage of adult patients with diabetes treated with aspirin or an antiplatelet agent	Active Health

*CSAC's decisions are forwarded to the NQF Board of Directors for Ratification.

Measure ID	Description	IP Owner
DIABETES		
EC-231-08 Diabetes with LDL greater than 100 – Use of a lipid lowering agent CSAC Decision*: Endorse	Percentage of adult patients with diabetes mellitus and an LDL value greater than 100 mg/dL with a current refill for a lipid lowering agent	Active Health
EC-232-08 Diabetes with Hypertension or Proteinuria - Use of an ACE Inhibitor or ARB CSAC Decision*: Endorse	Percentage of patients with diabetes and hypertension or proteinuria that have a current refill for an angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)	Active Health
EC-262-08 Diabetes and elevated HbA1c – Use of diabetes medications CSAC Decision*: Endorse	Percentage of patients 18- 75 years with diabetes and an elevated HbA1c that are receiving diabetic treatment (e.g., Metformin)	Active Health
EC-013-08 Comprehensive diabetes care: HgA1c control (<8%) © NCQA CSAC Decision*: Endorse	The percentage of members 18 - 75 years of age with diabetes (type 1 and type 2) who had HbA1c control (<8.0%).	NCQA
GASTROESOPHAGEAL: REFLUX DISEASE (GERD)		
EC-239-08 GERD - Upper Gastrointestinal Study in Adults with Alarm Symptoms CSAC Decision*: Endorse	Percentage of patients with gastroesophageal reflux disease (GERD)with alarm symptoms and who have had an upper gastrointestinal study	Active Health

*CSAC’s decisions are forwarded to the NQF Board of Directors for Ratification.

Measure ID	Description	IP Owner
GYNECOLOGY		
EC-002-08 Appropriate Work Up Prior To Endometrial Ablation Procedure CSAC Decision*: Endorse	To ensure that all women have endometrial sampling performed before undergoing an endometrial ablation	Health Benchmarks
HEPATITIS AND LIVER DISEASE		
EC-285-08 Chronic Liver Disease - Hepatitis A Vaccination CSAC Decision*: Endorse	Percentage of patients with chronic liver disease who have received a hepatitis A vaccine	Active Health
EC-046-08 Hepatitis C: Viral Load Test CSAC Decision*: Endorse	This measure identifies the percentage of patients with Hepatitis C (HCV) who began HCV antiviral therapy during the measurement year and had HCV Viral Load testing prior to initiation of antiviral therapy.	Resolution Health
HIV/AIDS		
EC-009-08 HIV Screening: Members at High Risk of HIV CSAC Decision*: Endorse	To ensure that members at increased risk of HIV infection be screened for HIV	Health Benchmarks
EC-003-08 Appropriate Follow-up for Patients with HIV CSAC Decision*: Endorse	To ensure that all members diagnosed with HIV receive at least biannual testing for CD4 and HIV RNA levels to monitor for disease activity	Health Benchmarks
HYPERLIPIDEMIA and ATHERSCLEROSIS		
EC-203-08 Hyperlipidemia (Primary Prevention)- Lifestyle Changes and/or Lipid Lowering Therapy CSAC Decision*: Endorse	Percentage of patients with coronary artery disease risk factors who have an elevated LDL and who have initiated therapeutic lifestyle changes or are taking a lipid lowering agent	Active Health

*CSAC's decisions are forwarded to the NQF Board of Directors for Ratification.

Measure ID	Description	IP Owner
HYPERLIPIDEMIA and ATHERSCLEROSIS		
EC-004-08 Adherence to Lipid Lowering Medication CSAC Decision*: Endorse	To ensure that members who are taking medications to treat hyperlipidemia filled sufficient medication to have at least 80% coverage during the measurement year	Health Benchmarks
EC-041-08 Dyslipidemia New Med 12-Week Lipid Test CSAC Decision*: Endorse	This measure identifies patients age 18 or older who started lipid-lowering medication during the measurement year and had a lipid panel checked within 3 months after starting drug therapy	Resolution Health
HYPERLIPIDEMIA and ATHERSCLEROSIS		
EC-217-08 Atherosclerotic Disease- Lipid Panel Monitoring CSAC Decision*: Endorse	Percentage of patients with coronary artery, cerebrovascular or peripheral vascular disease that have been screened for dyslipidemia with a lipid profile	Active Health
EC-288-08 Atherosclerotic Disease and LDL Greater than 100-Use of a Lipid Lowering Agent CSAC Decision*: Endorse	Percentage of adult patients with atherosclerotic disease and an LDL greater than 100 that are taking a lipid lowering agent	Active Health
MEDICATION MANAGEMENT		
EC-119-08 Lithium Annual Creatinine Test in the ambulatory setting CSAC Decision*: Endorse	This measure identifies the percentage of patients taking lithium who have had at least one creatinine test after the earliest observed lithium prescription during the measurement year	Resolution Health
EC-076-08 Lithium Annual Lithium Test in ambulatory setting CSAC Decision*: Endorse	This measure identifies the percentage of patients taking lithium who have had at least one lithium level test after the earliest observed lithium prescription during the measurement year	Resolution Health

*CSAC's decisions are forwarded to the NQF Board of Directors for Ratification.

Measure ID	Description	IP Owner
MEDICATION MANAGEMENT		
EC-077-08 Lithium Annual Thyroid Test in ambulatory setting CSAC Decision*: Endorse	This measure identifies the percentage of patients taking lithium who have had at least one thyroid function test after the earliest observed lithium prescription during the measurement year	Resolution Health
EC-051-08 Warfarin PT/ INR Test CSAC Decision*: Endorse		Resolution Health
EC-204-08 Warfarin - INR Monitoring CSAC Decision*: Endorse	Percentage of patients taking warfarin with PT/INR monitoring	Active Health
EC-027-08 Ambulatory Initiated Amiodarone Therapy: TSH Test CSAC Decision*: Endorse	This measure identifies the percentage of patients who had a TSH baseline measurement at the start of amiodarone therapy	Resolution Health
MENTAL HEALTH and SUBSTANCE USE DISORDERS		
EC-014-08 Follow-Up After Hospitalization for Mental Illness CSAC Decision*: Endorse	This measure assesses the percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental health disorders and who had an outpatient visit, an intensive outpatient encounter or partial hospitalization with a mental health practitioner. Two rates are reported: Rate 1. The percentage of members who received follow-up within 30 days of discharge Rate 2. The percentage of members who received follow-up within 7 days of discharge.	NCQA
MENTAL HEALTH and SUBSTANCE USE DISORDERS		
EC-032-08 Bipolar antimanic agent CSAC Decision*: Endorse	This measure identifies the percentage of patients with newly diagnosed bipolar disorder who have received at least 1 prescription for a mood-stabilizing agent during the measurement year	Resolution Health

*CSAC's decisions are forwarded to the NQF Board of Directors for Ratification.

Measure ID	Description	IP Owner
MENTAL ILLNESS		
EC-093-08 Adult(s) with Frequent Use of Acute Medications that also Received Prophylactic Medications CSAC Decision*: Endorse	This measure identifies adults with migraines who are frequently taking acute (abortive) medications and are also taking a prophylactic medication for migraine control	Ingenix
PRENATAL CARE		
EC-039-08 Diabetes and Pregnancy: Avoidance of oral hypoglycemic agents CSAC Decision*: Endorse	This measure identifies pregnant women with diabetes who are not taking an oral hypoglycemic agent	Resolution Health
EC-112-08 Pregnant women that had HBsAg testing CSAC Decision*: Endorse	This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy	Ingenix
EC-107-08 Pregnant women that had HIV testing CSAC Decision*: Endorse	This measure identifies pregnant women who had an HIV test during their pregnancy	Ingenix
EC-110-08 Pregnant women that had syphilis screening CSAC Decision*: Endorse	This measure identifies pregnant women who had a syphilis test during their pregnancy	Ingenix

*CSAC's decisions are forwarded to the NQF Board of Directors for Ratification.